Hawthorne Effect: A Distributed Model Reinvents Clinical Trials

article image

In a large and growing class of tech companies operating in decentralized clinical trials, Hawthorne Effect differentiates itself with a heritage based on the complexities of medtech, and an Uber-like model that comes to the patient.

In 2021, funding for companies in a relatively new category known as decentralized clinical trials (DCTs) has been plentiful. These businesses are developing models to streamline clinical trial workflow with technologies that connect study subjects, from whom data needs to be routinely gathered, to investigators. Since January, several companies, including Science 37, Curebase Inc., HumanFirst, Castor, Antidote Technologies Ltd., ObvioHealth USA Inc., and Hawthorne Effect have completed financing rounds raising double-digit sums. Upping the ante, Medable Inc. raised a $304 million Series D round in October, valuing the company at $2.1 billion.


This article is restricted to subscribers only.

To continue reading, select one of the options below:

Existing Subscriber?

Sign In to continue reading.

Need Multi-User Access?

Gain access for your entire organization.

Get Quote Check to see if your company already has access

Subscribe to Market Pathways:

Actionable intelligence exploring the people, challenges, and opportunities impacting the global medtech community.

Subscribe to Market Pathways
Sign up for All-Access

Join our global community with a subscription to both MedTech Strategist and Market Pathways for one low price.



We're here to help! Please contact us at: